At the end of the year and the beginning of the year, Jiangsu Hengrui Medicine Co.Ltd(600276) R & D and innovation achieved a good harvest: the State Drug Administration approved the listing of two innovative drugs of the company on the same day. So far, Jiangsu Hengrui Medicine Co.Ltd(600276) has reached 10 innovative drugs on the market.
Behind the accelerated centralized listing of innovative drugs is Jiangsu Hengrui Medicine Co.Ltd(600276) as a representative enterprise of China’s innovative drug industry, it has long adhered to the innovation driven development strategy and promoted the transformation of scientific research achievements to form a virtuous circle.
approved two class 1 new drugs
Jiangsu Hengrui Medicine Co.Ltd(600276) the two innovative drugs approved this time are darcilil hydroxyethyl sulfonate tablets and proline hengglijing tablets, both of which are class 1 new drugs.
Dulcie Lee is China’s first CDK4/6 inhibitor, and this approved indication is the treatment of recurrent or metastatic breast cancer with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative after endocrine therapy. The listing application was included in the priority review and approval procedure by the State Food and drug administration according to breakthrough treatment varieties in April 2021. As a new highly selective CDK4/6 inhibitor, Dahl Sealy has made innovations in the molecular structure of drugs. Its listing will strongly promote the accessibility of CDK4/6 inhibitors, and will bring new therapeutic options for more HR+/HER2- breast cancer patients.
Heng Ge Ling Jing is the first domestic innovative SGLT2 inhibitor approved for improving glycemic control in adults with type 2 diabetes. In recent years, Jiangsu Hengrui Medicine Co.Ltd(600276) has made extensive research and development of pipeline layout in the field of diabetes, and Jiangsu Hengrui Medicine Co.Ltd(600276) is the first innovative drug in the field. At present, hengglijing is still developing compound preparations with metformin and DPP4 inhibitors, which will provide more diversified choices for clinical application.
Prior to this, Jiangsu Hengrui Medicine Co.Ltd(600276) eight innovative drugs have been approved for marketing. At the beginning of the new year, two more models were added, once again reflecting Jiangsu Hengrui Medicine Co.Ltd(600276) strong R & D strength of innovative drugs. The pace of transformation of innovative achievements that are getting better indicates that Jiangsu Hengrui Medicine Co.Ltd(600276) R & D innovation is gradually entering the harvest period.
continuous high-intensity investment creates strong R & D strength
no pains,no gains. The accelerated harvest of innovative drugs is inseparable from Jiangsu Hengrui Medicine Co.Ltd(600276) long-term pipeline layout and reserve.
All along, Jiangsu Hengrui Medicine Co.Ltd(600276) is famous for its rich R & D pipelines. In addition to the 10 innovative drugs that have been listed, the company has more than 50 innovative drugs under clinical development, and more than 240 clinical trials have been carried out outside China. It has built a number of technical platforms with independent intellectual property rights, such as protein hydrolysis targeted chimera (protac), whole human antibody library and high-throughput antibody discovery, antibody drug conjugate (ADC), T cell engineers, structural biology, etc., covering the world’s cutting-edge technical fields and forming an echelon product pipeline.
In addition to the tumor field with obvious traditional advantages, Jiangsu Hengrui Medicine Co.Ltd(600276) also comprehensively arranges the non tumor field, realizing a wide coverage of autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, respiratory diseases, blood diseases, nervous system diseases and other fields. The approved new class of drugs for lowering blood sugar, Jiangsu Hengrui Medicine Co.Ltd(600276) , is a typical representative. In the 10 years of its research and development, Jiangsu Hengrui Medicine Co.Ltd(600276) has finally been approved to go public, expanding its coverage of innovative drugs to the field of diabetes.
Behind the “grinding a sword in ten years” is the continuous and huge investment in talents and funds. In recent years, Jiangsu Hengrui Medicine Co.Ltd(600276) R & D investment has maintained rapid growth year after year, reaching nearly 5 billion yuan in 2020, exceeding 4 billion yuan in the first three quarters of 2021, and R & D investment accounts for more than 20% of revenue. With sustained and high-intensity R & D investment, Jiangsu Hengrui Medicine Co.Ltd(600276) has increasingly improved its talent and scientific research system. The company has built a large-scale and professional global R & D team of more than 4500 people, and established scientific and technological platforms such as national enterprise technology center and postdoctoral scientific research workstation, national molecular targeted drug Engineering Research Center and “national major new drug creation” special incubator base, Lay a solid foundation for the continuous output of high-quality R & D achievements.
Deep ploughing and meticulous work finally ushered in thick accumulation and thin development. At present, the sales revenue of Jiangsu Hengrui Medicine Co.Ltd(600276) innovative drugs accounts for about 40% of the total revenue. Innovative drugs have become a new growth engine of the company. With long-term high-intensity R & D investment, the company’s R & D pipeline is expected to contribute more and better self-developed new drugs to meet clinical needs in the near future.
focus on the health needs of Chinese people and continue to promote pharmaceutical innovation
Better solving the unmet treatment needs of Chinese patients is the starting point and foothold of Jiangsu Hengrui Medicine Co.Ltd(600276) innovative R & D.
From this 2 newly approved new drugs: Dahl Sealy, as a new highly selective CDK4/6 inhibitor, is committed to providing new therapeutic options that are closer to the current status of HR+/HER2- patients with advanced breast cancer in China. Heng Ge Li Jing is trying to change the pattern of China’s hypoglycemic market, which is still dominated by traditional hypoglycemic drugs, and better serve the number one China type 2 diabetic patients in the world. In addition, Jiangsu Hengrui Medicine Co.Ltd(600276) the innovative drug pipeline under development also fully considers the current situation of diseases and patient needs in China, and strives to find solutions closer to Chinese patients.
At present, under the challenges of increasing market and policy uncertainty and increasingly homogeneous competition, China’s innovative drug industry is facing considerable pressure of transformation and upgrading. This requires that pharmaceutical innovation and R & D must focus on the needs of patients and be truly clinical value oriented. Jiangsu Hengrui Medicine Co.Ltd(600276) as a leading enterprise, it has long focused on the health needs of Chinese people, promoted R & D innovation, made solid investment and ushered in achievements, which is a positive demonstration for the whole industry.
We still need to go further. Sun piaoyang, chairman of Jiangsu Hengrui Medicine Co.Ltd(600276) said that in the new year, Jiangsu Hengrui Medicine Co.Ltd(600276) will continue to maintain the spirit of struggle and pragmatism, constantly adapt to the higher requirements brought by industrial reform, face the challenges, seek progress in stability, concentrate resources, focus on innovation, continue to promote internationalization, benefit patients and benefit people’s life and health.
(Economic Observer network)
